recurrent platinum drug resistant primary peritoneal cancer

DBCOND0020559Malignant and unspecified neoplasms gastrointestinal NEC

recurrent platinum drug resistant primary peritoneal cancer is the indication for 1 drug in DrugBank. It is covered by 6 curated, structured indications.

Classified under: Malignant and unspecified neoplasms gastrointestinal NEC
Indicated drugs: Bevacizumab

What you can answer from here — as of October 25, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

6Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

1Drug reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for recurrent platinum drug resistant primary peritoneal cancer share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account